Abstract:Respiratory syncytial virus (RSV) and influenza are among the most important causes of severe respiratory disease worldwide. Despite the clinical need, barriers to developing reliably effective vaccines against these viruses have remained firmly in place for decades. Overcoming these hurdles requires better understanding of human immunity and the strategies by which these pathogens evade it. Although superficially similar, the virology and host response to RSV and influenza are strikingly distinct. Influenza induces robust strain-specific immunity following natural infection, although protection by current vaccines is short-lived. In contrast, even strain-specific protection is incomplete after RSV and there are currently no licensed RSV vaccines. Although animal models have been critical for developing a fundamental understanding of antiviral immunity, extrapolating to human disease has been problematic. It is only with recent translational advances (such as controlled human infection models and high-dimensional technologies) that the mechanisms responsible for differences in protection against RSV compared to influenza have begun to be elucidated in the human context. Influenza infection elicits high-affinity IgA in the respiratory tract and virus-specific IgG, which correlates with protection. Long-lived influenza-specific T cells have also been shown to ameliorate disease. This robust immunity promotes rapid emergence of antigenic variants leading to immune escape. RSV differs markedly, as reinfection with similar strains occurs despite natural infection inducing high levels of antibody against conserved antigens. The immunomodulatory mechanisms of RSV are thus highly effective in inhibiting long-term protection, with disturbance of type I interferon signaling, antigen presentation and chemokine-induced inflammation possibly all contributing. These lead to widespread effects on adaptive immunity with impaired B cell memory and reduced T cell generation and functionality. Here, we discuss the differences in clinical outcome and immune response following influenza and RSV. Specifically, we focus on differences in their recognition by innate immunity; the strategies used by each virus to evade these early immune responses; and effects across the innate-adaptive interface that may prevent long-lived memory generation. Thus, by comparing these globally important pathogens, we highlight mechanisms by which optimal antiviral immunity may be better induced and discuss the potential for these insights to inform novel vaccines.

Influenza: Toward understanding the immune response in the young

Divergent macrophage induced lung pathology occurs between infants and adults during respiratory viral infection

The role of TGFβ in the development of Th17 and Treg cells during influenza viral infection in neonatal mice (137.6)

Development of Influenza-Specific CD4 T Cell-Mediated Immunity in Children Following Inactivated Influenza Vaccination

Microbiota-derived inosine programs protective CD8 T cell responses against influenza in newborns

Diverging patterns in innate immunity against respiratory viruses during a lifetime: lessons from the young and the old

Age-Related Changes to the Immune System Exacerbate the Inflammatory Response to Pandemic H1N1 Infection

Inflammasome Activity in Response to Influenza Vaccination Is Maintained in Monocyte-Derived Peripheral Blood Macrophages in Older Adults

Γδ T Cells Orchestrate the Induction of Protective Type 2 Immunity in Neonatal Influenza Infection

The Altered Neonatal CD8+ T Cell Immunodominance Hierarchy during Influenza Virus Infection Impacts Peptide Vaccination

Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus

Innate Immune Response to Influenza Virus at Single-Cell Resolution in Human Epithelial Cells Revealed Paracrine Induction of Interferon Lambda 1

Specific and Nonspecific Effects of Influenza Vaccines

The Protective Role of Γδ T Cells in Neonatal Influenza (INC1P.348)

Impact of patient characteristics on innate immune responses and inflammasome activation in ex vivo human lung tissues infected with influenza A virus

The Nature of Immune Responses to Influenza Vaccination in High-Risk Populations

Within-Host Influenza Viral Diversity in the Pediatric Population as a Function of Age, Vaccine and Health Status

New Insights from an Ex Vivo Model

On the relative role of different age groups during influenza A epidemics in Germany, 2002-2017

Immune Cellular Networks Underlying Recovery from Influenza Virus Infection in Acute Hospitalized Patients

Impaired NK cell antiviral cytokine response against influenza virus in small-for-gestational-age neonates